pairing of light and heavy chains; and (7) somatic mutation.'."' These protean molecular mechanisms confer the potential to produce an estimated 10" different antibodies.
IgH locus on chromosome 14q occurs using one of approximately 50 functional VH genes, one or more of 30 D genes, and one of 6 J H genes.""' The individual VH genes are categorized into one of seven VH families (VH 1 to vH7) that vary in size from 1 (VH6 and vH7) to 22 (vH3) functional members defined by >80% sequence h~m o l o g y . '~. '~ Most studies have determined that the VH gene family usage in the normal human B-cell antibody repertoire is proportional to the number of functional germline genes within each VH family.'"** However, individual VH genes such as VH4.21 are clearly overrepresented in the normal B-cell repertoire.".""" Increased usage of VH4.21 also occurs in pathologic states, including autoimmune diseases (eg, cold agglutinin disease, systemic lupus erythematosus [SLE] ) and B-cell neoplasms [eg, chronic lymphocytic leukemia (CLL), diffuse large cell lymphoma (DLCL)] associated with autoimmune phenomgene in acute lymphoblastic leukemia (ALL) and Multiple myeloma (MM) is a B-cell malignancy characterized by the bone marrow (BM) accumulation of a clonal population of the most terminally differentiated B lymphocyte, the plasma cell, which secretes a monoclonal 1gH protein. The repertoire of VH genes used in MM has not been reported, although a few studies have incidentally identified the VH gene rearranged in small cohorts of MM patients.i7-iy Because autoimmune phenomena are rarely observed in MM, one may anticipate that VH4.21 would be underrepresented in this B-cell neoplasm. In the current study, we analyzed the VH gene usage in a large cohort of patients with MM to assess the overall representation of VH gene families, as well as specific VH genes. With an increasing body of evidence that MM originates from cells late in B-cell devel~prnent,'~.~" we sought to compare the VH gene usage of our cohort of MM patients to that reported in normal and malignant B cells at earlier stages of B-cell differentiation to gain insight into the role of clonal selection during B-cell ontogeny. The heparinized sample was layered over Histopaque 1077 (Sigma, St Louis, MO), and the mononuclear layer was obtained after density centrifugation and washed three times in phosphate-buffered saline (PBS) after exposure to red blood cell (RBC) lysis buffer (Sigma).
Myeloma V , gene determination. Total RNA was extracted using the guanidine isothiocyanate method from 30 X 10' BM mono- sayed by exposure to ultraviolet (UV) light. Myeloma variable gene sequencing If a prominent PCR product was obtained, it was purified by electrophoresis through a 1.6% agarose gel and excision of the appropriately sized band.'"' The product was ligated into a plasmid vector and then used to transform E. coli strain XLI-Blue bacteria. Colonies containing an appropriately sized insert were sequenced using the Sequenase II kit (US Biochemicals, Cleveland, OH) according to manufacturer's instructions with '"S a-dATP (Amersham, Arlington Heights, 1L). The identical sequence obtained from a minimum of three clones was then compared with the most homologous germline genes using the DNASIS 1.1 program (Hitachi, San Bruno, CA).
Northern blot ana/wis. Northern blot analyses, including transfer, hybridization, and washing, were performed after electrophoresis of 20 pg of total RNA through a 1.2% agarose gel containing formaldehyde?' RNA was transferred to a nylon membrane (Schleicher & Schuell, Keene, NH) and then hybridized to Y -'~ P-labeled VHI-6 family probes (labeled with DNA 5' Endlabeling Kit, Boehringer Mannheim, Indianapolis, IN) according to manufacturer's recommendations. (The VH7 family had not been identified at the time of Northern blotting). &actin probes were used for positive controls. Hybridization was performed at 42°C overnight. than the one representing the V, family of the MM clone, primarily in patients with less myelomatous BM involvement. Due to the suppression of normal immunoglobulin synthesis in MM patients, the background of smears representing a polyclonal B-cell population is often more faint than the pattern observed in normal patients. This phenomenon facilitates the detection of a predominant RT-PCR band in MM patients. Nonetheless, the MM sequence was not identified in 16 patients, because a predominant RT-PCR product was not detected (14 patients) or because multiple sequences were obtained (two patients). As we have previously reported," Northern blotting on BM mononuclear cell RNA with the same V,, family primers as probes was performed on the first IO patients with a predominant RT-PCR band. In all IO patients, a 2.3-kb band was detected only with the VH family probe that was used as the V, family primer, which yielded a predominant RT-PCR band (Fig  2) .JJ Moreover. RT-PCR of BM RNA from normal donors yielded gel patterns (multiple distinct. but faint bands) consistent with a polyclonal B-cell source (Fig 3) .
RESULTS

Reverse transcriptase (RT) PCR.
V, ,family usage in MM porients. The cDNA from 72 MM patients was successfully cloned and sequenced. Three to I6 clones were sequenced for each patient, and each clone yielded the same sequence for all patients, except for rare random errors due to Tnq polymerase.'"' The VH family and most homologous germline V, gene rearranged in the MM clone is shown for each patient in Table 2 . Except for vH7, representatives of all V, families were detected. The frequency of V, family usage in decreasing order was VH3 to the functional germline complexity of the V, families (Table 3) . None of the V, families demonstrated biased usage compared with its germline complexity.
Inrlivihtol V , gene rtsnge i n MM pnrienrs. A total of 35 of the 48 (72.9%) known functional V, genes were rearranged in our cohort of 72 patients."." The number of different V, genes detected from each V, family was propor>v,4 >v,I >v115 > v~2 >v& >v,7 and corresponded 3  3  3  3  3  3  3  3  3  3  3  3  3  3  3  3  3  3  3  3  3  3  3  3  3  3  3  3  3  4  4  4 tional to the functional germline complexity of each family (Table 3) . The frequency of different VH genes used expressed as a percentage of the known number of functional genes per family ranged from 0.0% (vH7) to 100.0% (VH5); for the largest family, vH3, 14 of 22 (63.6%) known functional genes were detected (Table 3) .
The VH gene most frequently used was 3-30 (DP-49) and represented 6 of 72 (8%) of the cases. The second most common gene was VH3-23 [5 of 72 (7%)], which was actually relatively underrepresented compared with normal VH gene usage, in which this gene may be functionally rearranged in more than 17% of circulating B VH genes 1-69 and 3-9 were both detected in four cases, and all other genes were noted in three or fewer cases. The VH4.21 gene was not detected in any of the 72 patients we evaluated. Moreover, none of the 14 members of the vH4 family that were identified in our cohort shared significant homology with VH4.21 (range, 78.0% to 86.6% homology; Table 4 ). In these 14 cases, the VH sequences were markedly less homologous to V4.21 than to the most homologous germline gene (range, 4.4% to 8.8%; Table 4 ).
As previously reported in a subset of this the cDNA sequences were marked by a high degree of somatic mutation with an average of 8.8% mutated nucleotides per sequence (range, 2.7% to 16.5%). The percentage of somatic mutation did not vary significantly with respect to the VH family used by the MM clone (VH] = 9.3%, vH2 = 7.7%, v~3 = 8.7%, vH4 = 9.5%, vH5 = 6.9%, v~6 11.2%).
DISCUSSION
We successfully identified the VH family and VH gene in 72 of 88 patients known to have had circulating monoclonal IgH at some point in their disease history. The majority of the 16 patients for whom no sequence was obtained were in plateau phase (eg, either no detectable or a very small Mspike in the serum by protein electrophoresis) after chemotherapy, which rendered the malignant clone's VH gene sequence difficult to identify with certainty by RT-PCR. The VH family usage in the remaining 72 patients closely corresponded to the functional germline complexity of the VH families (Table 3) , a finding that is consistent with the published data on usage in the normal B-cell Based on an assumption of completely random rearrangement of VH genes (48 functional genes should yield an anticipated gene frequency of approximately 2%), we determined that specific VH genes, VH3-30 (6 of 72 or 8%) and VH3-23 (5 of 72 or 7%), were distinctly overrepresented. Previous studies have reported the increased usage of these same genes in normal B cells and other B-cell neoplasms, perhaps due to positive clonal selection or to molecular mechanisms that predispose to their preferential rearrangement.'9.23 However, the finding of increased usage of VH1-69 and vH3-9 (4 of 72 or 6% for both genes) in our cohort is unique to MM. In contrast to VH3-30 and VH3-23, the frequent usage VH1-69 and vH3-9 in MM cannot be explained by preferential molecular rearrangement, because these latter two genes are rarely expressed in other malignant and nonmalignant B-cell populations.'9~2"'6 A role for positive selection may be invoked, as these genes may express antibodies with unique and beneficial antigen binding capabilities. Alternatively, terminally differentiated B cells, which have rearranged these genes, may be predisposed to malignant transformation.
The VH4.21 gene is markedly overrepresented in the normal B-cell repertoire (range, 26% to 8%)2"26~29 in autoimmune diseases,30,32 and in B-cell neoplasms other than occurs in 4% to 22% and 9% to 33% of cases, respectively; this gene is rearranged in a striking 65% (1 1 of 17) of DLCL has not been studied, and, to date, none of the nine previously published MM sequences has rearranged this gene.3y.4', 42 In sharp contrast to other B-cell neoplasms, VH4.21 gene rearrangement was not observed in any of our 72 patients, although one fifth of the patients used other members of the The complete absence of VI,4.21 in our cohort of 72 patients has three important implications. First, the absence of this gene may point to a partial explanation for the lack of autoimmune phenomena in MM. B-cell neoplasms that do manifest autoimmune phenomena (CLL and DLCL) rearrange VH4.21 with increased frequency, although recent studies suggest that the monoclonal antibody produced by the malignant cells in CLL does not always cause the autoimmune hemolytic anemia.4'.4h A pathogenic role for antibodies expressed by this specific VH gene in autoimmune disease states is implicated by the fact that these antibodies demonstrate affinity for a number of self-antigens (eg, the i and I RBC antigens, striated muscle, ssDNA, and dsDNA).28 Moreover, pathogenic monoclonal cold agglutinins have shown an absolute VH4.2 1 gene restri~tion.'"~~ Nonetheless, the absence of VH4.21 by itself cannot account for the paucity of autoimmune phenomena in MM, because autoantibodies can be encoded by multiple different VH genes other than VH4.21 and because the generation of high-affinity antibodies to a large extent occurs as a result of somatic rearrangement and mutation of the CDR3.
Second, the lack of VH4.21 usage may suggest that cells, which have successfully rearranged this gene and therefore have the potential to secrete antibodies capable of recognizing self-antigens, are clonally deleted during the process of terminal differentiation of B cells into antibody-secreting plasma cells. This interpretation stems from the fact that normal germinal center B cells, as well as B-cell neoplasms, arrested at earlier stages of B-cell ontogeny (ie, CLL, ALL, and DLCL) demonstrate overusage of VH4.21 .24.27.2'),1',22.24.3(, This conclusion is also strengthened by a study by Kraj et al" who showed that a monoclonal antiidiotype antibody (9G4), which specifically recognizes the idiotope expressed by V,,4.21, detected IgM, but not IgG antibodies in the serum. Expression of this idiotope is rarely lost by somatic mutation so that the 9G4 antibody should be inherently capable of detecting the antibody secreted by IgG-expressing cells.3' Clonal deletion (or, alternatively, the induction of an anergic state) of VH4.21 expressing B cells before isotype switching serves as an explanation for decreased serum IgG relative to IgM. If one assumes that clonal deletion of VH4.21 expressing cells does indeed occur and that clonal deletion is a process that B cells undergo during antigen driven stages of differentiation, then the lack of VH4.2 1 usage implies that the final oncogenic event in MM occurs at a terminal step in B-cell differentiation. This latter conclusion is further substantiated by the observation that MM, among all B-cell neoplasms, manifests the highest rate of somatic mutation without intraclonal diversity of the rearranged VH Finally, VH4.2 I does not promote the malignant transformation or growth of MM, whereas the increased usage of this gene in CLL, ALL, and especially DLCL relative to normal B-cell populations suggests that the interaction of the IgH product of this gene with self-antigens may function to stimulate oncogenesis, proliferation, and perpetuation of these B-cell neoplasms. The marked overusage of VH4.21 in DLCL implies an important role for this gene in the development of this neoplasm." An alternative explanation for the inability to detect Vt,4.21 gene rearrangement in MM patients is that the gene is successfully rearranged in B cells, but these cells become functionally inactive (ie, anergic) and do not secrete detectable levels of monoclonal 1gH. If this were the case, one might expect to detect VH4.21 rearrangements in MM patients who were nonsecretors of' IgH. An inability of our V,,4 family-specific primer to amplify the Vt,4.21 gene due to lack of homology to the VH4.21 leader sequence cannot account for the complete absence of this gene in our cohort of MM patients. The identical primer has been used to identify VH4.2 1 rearrangement in normal pcripheral blood B lymphocytes in our laboratory (data not shown) and others'."-'"
A recent study by Brezinschek et a]'') demonstrated the increased usage of vH3-49 and vH3-53 in normal peripheral blood B cells. Similar to VH4.21, these two genes were not detected in any of our patients. A physiologic role for clonal deletion does not readily explain the absence of these genes in our cohort. as these genes have not been reported to be involved in autoimmune phenomena or recognition of selfantigens.
In summary, the VH gene usage in MM is unique compared with that in malignant and nonmalignant B-cell populations. The physiologic process of clonal deletion may function to remove clones that have rearranged V,, genes (VH4.21) capable of expressing antibodies that recognize self-antigens. The complete lack of VH4.21 gene rearrangement may help to partially explain the paucity of autoimmune phenomena in MM. Unlike other B-cell neoplasms, VH4.21 does not seem to play a role in the development of MM.
